Skip to Content

Join the 'Reclast' group to help and get support from people like you.

Reclast News

Powerful Drug for Advanced Cancers May Need Less Frequent Dosing

Posted 4 Jan 2017 by Drugs.com

WEDNESDAY, Jan. 4, 2017 – Use of a bone cancer drug once every three months, instead of monthly, does not boost the risk of bone problems over two years, a new study finds. That could reduce side effects from the drug, known as zoledronic acid (Zometa), and increase cost savings, the researchers said. The drug is used to treat the spread of breast cancer, prostate cancer and multiple myeloma to...

FDA Medwatch Alert: Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment

Posted 2 Sep 2011 by Drugs.com

ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk of kidney failure. Cases of acute renal failure requiring dialysis or having a fatal outcome following Reclast use have been reported to FDA. The revised label states that Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min or...

FDA Medwatch Alert: Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication - Potential Increased Risk of Esophageal Cancer

Posted 21 Jul 2011 by Drugs.com

Includes: Fosamax (alendronate), Actonel (risedronate), Boniva (ibandronate), Atelvia (risedronate delayed release), Didronel (etidronate), and Skelid (tiludronate) ISSUE: FDA notified healthcare professionals and patients about its ongoing review of data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus....

FDA Medwatch Alert: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)

Posted 7 Jan 2008 by Drugs.com

[Posted 01/07/2008] FDA informed healthcare professionals and patients of the possibility of severe and sometimes incapacitating bone, joint, and/or muscle (musculoskeletal) pain in patients taking bisphosphonates. Although severe musculoskeletal pain is included in the prescribing information for all bisphosphonates, the association between bisphosphonates and severe musculoskeletal pain may be...

Ask a Question

Further Information

Related Condition Support Groups

Osteoporosis, Prevention of Osteoporosis

Reclast Patient Information at Drugs.com